Synthetic Human Secretin in Children With Autism
- Conditions
- Autism
- Registration Number
- NCT00036244
- Lead Sponsor
- Repligen Corporation
- Brief Summary
The purpose of the study is to determine whether multiple doses of secretin are safe and effective in the treatment of children with autism.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- Not specified
Not provided
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (15)
Southwest Autism Research Center
🇺🇸Phoenix, Arizona, United States
Children's Hospital and Research Center at Oakland
🇺🇸Oakland, California, United States
Puget Sound Neurology
🇺🇸Edmonds, Washington, United States
UCLA Pediatric Neurology
🇺🇸Los Angeles, California, United States
Miami Children's Hospital
🇺🇸Miami, Florida, United States
University of Medicine and Dentistry of New Jersey
🇺🇸Newark, New Jersey, United States
Riley Children's Hospital
🇺🇸Indianapolis, Indiana, United States
Alachua Family Psychiatry
🇺🇸Gainesville, Florida, United States
1st Allergy & Clinical Research Center
🇺🇸Centennial, Colorado, United States
Hardy Healthcare Associates
🇺🇸Hingham, Massachusetts, United States
The Ohio State University
🇺🇸Columbus, Ohio, United States
Children's Hospital of Michigan
🇺🇸Detroit, Michigan, United States
Schneider Children's Hospital
🇺🇸New Hyde Park, New York, United States
Children's Biomedical Center of Utah
🇺🇸Sandy, Utah, United States
The Clinical Trials Center:A Division of Children's Hospital
🇺🇸Metairie, Louisiana, United States